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D-Cycloserine is an effective second-line drug against Mycobacterium avium and Mycobacterium tuberculosis.
To analyze the genetic determinants of D-cycloserine resistance in mycobacteria, a library of a resistant Myco-
bacterium smegmatis mutant was constructed. A resistant clone harboring a recombinant plasmid with a 3.1-kb
insert that contained the glutamate decarboxylase (gadA) and D-alanine racemase (alrA) genes was identified.
Subcloning experiments demonstrated that alrA was necessary and sufficient to confer a D-cycloserine resis-
tance phenotype. The D-alanine racemase activities of wild-type and recombinant M. smegmatis strains were
inhibited by D-cycloserine in a concentration-dependent manner. The D-cycloserine resistance phenotype in the
recombinant clone was due to the overexpression of the wild-type alrA gene in a multicopy vector. Analysis of
a spontaneous resistant mutant also demonstrated overproduction of wild-type AlrA enzyme. Nucleotide se-
quence analysis of the overproducing mutant revealed a single transversion (G3T) at the alrA promoter, which
resulted in elevated b-galactosidase reporter gene expression. Furthermore, transformants of Mycobacterium
intracellulare and Mycobacterium bovis BCG carrying the M. smegmatis wild-type alrA gene in a multicopy vector
were resistant to D-cycloserine, suggesting that AlrA overproduction is a potential mechanism of D-cycloserine
resistance in clinical isolates of M. tuberculosis and other pathogenic mycobacteria. In conclusion, these results
show that one of the mechanisms of D-cycloserine resistance in M. smegmatis involves the overexpression of the
alrA gene due to a promoter-up mutation.
The resurgence of tuberculosis has been characterized by
the emergence of significant numbers of drug-resistant strains.
Furthermore, microorganisms of the Mycobacterium avium
complex, opportunistic pathogens common in AIDS patients,
are inherently resistant to many traditional antimycobacterial
agents (20, 23). Hence, the development of novel drugs for the
treatment of atypical infections by M. avium, Mycobacterium
intracellulare, and multiple-drug-resistant Mycobacterium tuber-
culosis is urgently needed.
The mycobacterial cell wall is an effective barrier that con-
tributes to drug resistance (45). Inhibitors of cell wall biosyn-
thesis not only are potential antimycobacterial agents but also
increase mycobacterial susceptibility to other antimicrobial
agents (36). One inhibitor of cell wall synthesis is D-cycloserine
(D-4-amino-isoxazolidone [DCS]), a cyclic structural analog of
D-alanine (31). D-Amino acids, especially D-alanine, D-gluta-
mate, and D-aminopimelate, are important components of all
bacterial cell walls, including those of mycobacteria. Alanine is
usually available as the L stereoisomer, and the conversion to
D-alanine by the cytoplasmic enzyme D-alanine racemase (25)
is required for the initial step in the alanine branch of pepti-
doglycan biosynthesis. D-Alanine is converted to the dipeptide
D-alanyl–D-alanine in a reaction catalyzed by D-alanyl:alanine
synthetase (D-alanine ligase [30]). In Escherichia coli, both
D-alanine racemase and D-alanine ligase are targets of DCS
(26, 31, 33). Moreover, the biosynthesis of mycolyl-arabinoga-
lactan-peptidoglycan complex is inhibited by DCS in M. tuber-
culosis (10), and biochemical studies indicated that D-alanine
ligase is one of the targets in mycobacteria (11).
DCS is an effective antimycobacterial agent but is rarely
prescribed and used only in combined therapies due to its
adverse effects (21, 22, 54). These side effects are due to bind-
ing of DCS to neuronal N-methyl aspartate receptors (44) and
inhibition of enzymes that metabolize and synthesize the neu-
rotransmitter g-aminobutyric acid (53). Nevertheless, DCS is
an excellent candidate for the development of a new genera-
tion of antibiotics. Two important considerations predict that
rationally designed derivatives of DCS may be more efficacious
antimicrobial agents. First, DCS targets participate in essential
steps of cell wall synthesis. Second, DCS resistance has not yet
become an important clinical problem. Therefore, the identi-
fication of DCS targets and the elucidation of the mechanisms
leading to DCS resistance may contribute to the development
of new therapeutics with fewer side effects and mechanisms of
action which do not favor the emergence of resistance.
Few studies on the mode of action and mechanisms of DCS
resistance in mycobacteria have been conducted. David (9)
isolated and characterized step-wise DCS-resistant (DCSr)
mutants of M. tuberculosis and discovered mutants that showed
either normal or reduced cellular permeability to DCS. It was
hypothesized that mutants with normal uptake carried muta-
tions in the D-alanine ligase gene, but no biochemical or mo-
lecular evidence in support of this hypothesis was provided.
Here we describe the first molecular genetic analysis of DCS
resistance in mycobacteria, which led to the identification of
one of the DCS targets and resistance mechanisms in Myco-
bacterium smegmatis. A spontaneous DCSr mutant strain of M.
smegmatis exhibited a promoter-up mutation in the D-alanine
racemase gene (alrA) which increased the levels of expression
* Corresponding author. Mailing address: Department of Veteri-
nary and Biomedical Sciences, 211 VBS, Fair St. and East Campus
Loop, University of Nebraska, Lincoln, NE 68583-0905. Phone: (402)
472-8543. Fax: (402) 472-9690. E-mail: braul@crcvms.unl.edu.
5046
 at UNIV O
F NEBRASKA-LINCO
LN on Septem






of the gene and determined a DCSr phenotype. Furthermore,
transformants of M. intracellulare and M. bovis BCG with the
M. smegmatis alrA gene carried in a multicopy vector had a
DCSr phenotype, indicating that a similar mechanism of resis-
tance may occur in pathogenic mycobacteria.
MATERIALS AND METHODS
Bacterial strains, plasmids, and culture conditions. Bacterial strains and plas-
mids used in this study are listed in Table 1. E. coli strains were grown in
Luria-Bertani broth or agar. M. intracellulare strains were grown as previously
described (16). M. smegmatis strains were grown at 37°C with shaking (200 rpm;
Innova 4300 incubator shaker; New Brunswick Scientific, Edison, N.J.) in
Middlebrook 7H9 broth (BBL Microbiology Systems, Cockeysville, Md.), Luria-
Bertani broth, or minimal medium (55) in the presence of 0.05% Tween 80.
Tryptic soy agar base (Difco Laboratories, Detroit, Mich.) was used for growth
of M. smegmatis on solid media. Spontaneous DCS-resistant M. smegmatis mu-
tants were isolated by plating approximately 5.0 3 109 exponentially growing
cells on tryptic soy agar with 500 to 600 mg of DCS ml21. Since DCS is moder-
ately unstable, agar plates containing DCS were kept at 4°C for a maximum of 2
days. The independent mutants GPM14 and GPM16 were isolated at 500 and
600 mg ml21, respectively, from the susceptible parent strain mc2155 (Fig. 1). To
determine inhibition of colony formation, appropriate dilutions of exponentially
growing cells (5.0 3 108 to 1.0 3 109 CFU ml21) were plated in triplicate onto
agar containing a maximum of 1,500 mg of DCS ml21 for M. smegmatis or up to
250 mg of DCS ml21 for M. intracellulare. Regression analyses of bacterial titers
at different DCS concentrations were conducted by using Proc Reg (SAS Insti-
tute, Cary, N.C.). The reduced model for the different bacterial strains was tested
against the full model for lack of fit for each of the mycobacterial species tested.
A significant lack of fit indicated that the responses to the DCS concentrations
were different between the strains. If a significant lack of fit was determined when
all the strains were considered, subsets of strains were also compared.
For D-alanine racemase assays, M. smegmatis cells were grown in minimal
medium (55) to mid-exponential phase (ca. 3.0 3 108 CFU ml21). For b-
galactosidase assays, the M. smegmatis strains were grown in Middlebrook 7H9
broth to mid-exponential phase (ca. 3.0 3 108 CFU ml21).
Transformation of E. coli and mycobacteria was carried out as described
previously (16). E. coli and M. intracellulare transformants were selected at 50 mg
of kanamycin ml21. M. smegmatis transformants were selected at either 10 mg of
kanamycin ml21 or 10 mg of kanamycin (Sigma Chemical Co., St. Louis, Mo.)
ml21 plus 300 mg of DCS (Sigma or Aldrich Chemical Co., Inc., Milwaukee,
Wis.) ml21.
Oligonucleotides, PCR amplifications, and probe labeling. The oligonucleo-
tide primers (Ransom Hill Biosciences, Inc., Ramona, Calif.) for PCR amplifi-
cation of the D-alanine racemase genes from pBUN66 and GPM14 were JIM-1
(59-GNGAYYNYGGRTACACCGAGTTC-39) and JIM-2 (59-CGNCGRCG
AGCNNCTCGAAATC-39). The oligonucleotide primer pair for probe labeling
by PCR was NAN-1 (59-TCTGCGGCCTCTGGGACAATGGG-39) and NAN-2
FIG. 1. Inhibition of CFU at increasing DCS concentrations for M. smegma-
tis mc2155 (open circles), DCS-resistant mutant GPM14 (closed squares), DCS-
resistant mutant GPM16 (closed circles), mc2155(pMV262) (open triangles), and
mc2155(pBUN19) (closed triangles). The curves were generated from data from
a representative experiment. For statistical analysis, performed for at least two
independent experiments for each strain, see the text.
TABLE 1. Strains and plasmids used in this study
Strain or plasmid Relevant characteristics Source or reference
E. coli DH5a recA lacZDM15 Gibco-BRL
M. smegmatis mc2155 High-transformation mutant of M. smegmatis ATCC 607 41
M. smegmatis GPM14a M. smegmatis first-step DCSr spontaneous mutant derived from mc2155; overproduces
D-alanine racemase
This work
M. smegmatis GPM16 M. smegmatis first-step DCSr spontaneous mutant derived from mc2155 This work
M. intracellulare mc276 Highly transformable M. avium complex strain W. R. Jacobs, Jr., 16
M. bovis BCG French isolate (Pasteur substrain) W. R. Jacobs, Jr.
pCV77 Replicating E. coli-Mycobacterium shuttle plasmid; carries cassette of the promoterless
lacZ gene with ribosome-binding site outflanked by transcriptional terminators
MedImmune Inc.
pMV203 Replicating E. coli-Mycobacterium shuttle plasmid; precursor of pMV262 without Phsp60 MedImmune Inc.
pMV262 Replicating E. coli-Mycobacterium shuttle plasmid; carries Phsp60 promoter upstream
from polylinker site
MedImmune Inc., 7
pYUB178 Integration-proficient shuttle cosmid vector; integrates at the attachment site of myco-
bacteriophage L5
34
pBUN19 pMV262 with the 3.1-kb insert from GPM16 in the BamHI site This work
pBUN25 pMV262 with the 0.9-kb PstI fragment of pBUN19 in the PstI site This work
pBUN47D pMV262 with the 2.0-kb PstI fragment of pBUN19 in the PstI site This work
pBUN66 Recombinant plasmid isolated from an M. smegmatis mc2155 cosmid library which hy-
bridized with the 3.1-kb insert of pBUN19
24, W. R. Jacobs, Jr.,
this work
pBUN82 pMV262 with the 1.9-kb ScaI/HindIII fragment of pBUN19 in the PvuII/HindIII site This work
pBUN83 pMV262 with the 2.0-kb DraI/ClaI fragment of pBUN19 in the DraIClaI site This work
pBUN92 pMV203 with the 2.9-kb EcoRI/EcoRV fragment of pBUN19 in the EcoRI/HpaI site This work
pBUN101 pCV77 with the 0.5-kb fragment containing the upstream noncoding region of the alrA
gene from mc2155 inserted at the polylinker site
This work
pBUN102B pCV77 with the 0.5-kb fragment containing the upstream noncoding region of the alrA
gene from GPM14 inserted at the polylinker site
This work
a GPM, Great Plains Mycobacterial Collection.
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(59-GACACACCTGCCACGGTGCCGAC-39). The amplifications of the up-
stream, noncoding regions of the D-alanine racemase genes from mc2155 and
GPM14 were done with JIM-2 and JIM-3 (59GTGTGGCGCAACAAAGAG-
39). PCR amplifications were carried out with Taq DNA polymerase (Fisher
Scientific Co., Pittsburgh, Pa.) for 30 cycles in a thermal cycler (Perkin-Elmer
GeneAmp PCR System 2400; Roche Molecular Systems, Branchburg, N.J.) and
required 10 mM Tris-HCl (pH 8.3), 2.5 mM MgCl2, 0.2 mM deoxynucleoside
triphosphate, 0.2 mM spermidine, 10% (vol/vol) dimethyl sulfoxide, and 0.1 mg
of gelatin ml21 under standard cycling temperatures (hot start at 95°C, denatur-
ation at 94°C, annealing at 55°C, and polymerization at 72°C). For radioactive
labeling, 10 cycles were run in the presence of 50 mCi of [a-32P]dATP. The
Expand high-fidelity PCR system (Boehringer Mannheim Biochemicals, India-
napolis, Ind.) was used as recommended by the manufacturer.
Nucleic acid manipulations, DNA sequencing, and primer extension analysis.
For restriction digestions, ligations, agarose gel electrophoresis, and Southern
hybridizations under stringent conditions, standard procedures were followed as
previously described (40). Chromosomal DNA from M. intracellulare strains, M.
paratuberculosis, and M. smegmatis was prepared as described previously (51).
Chromosomal DNA from BCG and M. tuberculosis was provided by W. R.
Jacobs, Jr., and T. Weisbrod.
Total RNA from mc2155, GPM14, and GPM16 was isolated by following the
procedure described by Bashyam and Tyagi (3). Northern blotting was done as
previously described (1). Quantification of mRNA was carried out by capturing
the images from the autoradiograms with a Kaiser RS-1 video camera and a
Northern Light model 890 illuminator (Kaiser Optical Systems, Inc., Ann Arbor,
Mich.) and analyzing the output with NIH Image 1.49 software. The levels of
RNA were normalized by the amount of rRNA.
Sequencing reactions were carried out with the Taq DyeDeoxy FS terminator
cycle sequencing kit (The Perkin-Elmer Corp., Norwalk, Conn.). The unincor-
porated dye terminators and primers were separated from the extension products
by spin column purification (Centri-Sep; Princeton Separations, Adelphia, N.J.).
The samples were dried, resuspended in loading buffer, heat denatured, and
loaded in ABI model 377 DNA sequencers (Applied Biosystems, Foster City,
Calif.). Each template was sequenced in its entirety in both orientations to
prevent potential errors in sequencing. DNA sequencing and nucleotide se-
quence analyses were performed at the University of Minnesota’s Advanced
Genetic Analysis Center (St. Paul). Protein sequence analysis was performed
with the Genetics Computer Group package (version 8.1), University of Wis-
consin (13).
For the assessment of promoter strength by b-galactosidase reporter gene
assays, 1.8-kb DNA fragments were amplified with primers JIM-2 and JIM-3, the
products were digested with ScaI and ClaI, and the resulting 0.5-kb fragments
were directionally cloned into the ClaI and the blunt-ended PstI sites of pCV77.
The synthesis of blunt-ended termini was carried out with Pfu DNA polymerase
as instructed by the supplier (Stratagene, La Jolla, Calif.). All constructs were
verified by sequencing of the relevant regions.
Primer extension analysis of alrA mRNA was carried out as described previ-
ously (12). The oligonucleotide NAN-3 (59-ATCGATCACCGTCTGTGCCG
ACGCC-39) was radiolabeled with [g-32P]ATP by using T4 polynucleotide kinase
(Promega). The reactions were extended with Moloney murine leukemia virus
reverse transcriptase (Promega). Radioactivity in primer extension bands was
quantified with a PhosphorImager by using ImageQuant software version 3.3
(Molecular Dynamics, Sunnyvale, Calif.).
M. smegmatis genomic libraries. An M. smegmatis mc2155 cosmid library was
kindly provided by W. R. Jacobs, Jr. For M. smegmatis GPM16 genomic libraries,
chromosomal DNA was partially digested with Sau3A, and fragments with an
average size of 3.0 kb were purified from a 0.8% agarose gel and ligated into the
BamHI site of the E. coli-Mycobacterium shuttle plasmid pMV262 (7), which
carries the kanamycin-resistant marker and the strong promoter Phsp60. The
ligation mixture (approximately 1.0 mg of vector DNA) was transformed into M.
smegmatis mc2155. For selection of DCS resistance determinants, cells were
plated on 10 mg of kanamycin ml21 plus 300 mg of DCS ml21 and yielded two
DCS-resistant clones. Parallel platings of the transformation mixture on 10 mg of
kanamycin ml21 indicated a transformation efficiency of 4 3 104. Plasmids were
isolated from independent kanamycin-resistant transformants and analyzed in E.
coli for the presence of M. smegmatis inserts. This analysis revealed approxi-
mately 10% recombinant plasmids. Hence, the two DCS-resistant clones resulted
from a representative library of ca. 4,000 recombinants.
Preparation of crude cell extracts. Cells were harvested and concentrated
20-fold in 50 mM Tris-HCl (pH 8.0). Cells were kept on a salt-ice-water bath and
sonicated with a Vibra-Cell model VC600 disrupter (Sonic and Materials, Inc.,
Danbury, Conn.). Sonication was carried out for 10 min at 80% power output
and 50% duty cycle, and in the presence of one-third the final volume of type A-5
alumina (Sigma). The resulting extracts were centrifuged at 4°C in a JA-17 rotor
(Beckman Instruments, Inc., Fullerton, Calif.) for 30 min at 15,000 rpm, dialyzed
against 50 mM Tris-HCl (pH 8.0), and sterilized by filtration through a 0.22-mm-
pore-size filter. The protein concentration was determined by the DC assay
(Bio-Rad Laboratories, Richmond, Calif.) as recommended by the manufac-
turer.
Enzyme assays. D-Alanine racemase activity in crude extracts was assayed in
the direction of the conversion of L-alanine into D-alanine by a modification of
the coupled spectrophotometric method described by Wijsman (52). Pilot exper-
iments were performed to determine the amount of each extract and incubation
times (15 min) resulting in a linear conversion of the substrate into the product.
Crude cell extracts were incubated at 37°C in 1.0 ml each of reaction mixtures
containing 50 mM Tris-HCl (pH 8.0), 0.1 mM pyridoxal phosphate (Sigma), and
15 mM L-alanine (Sigma). To start the reactions, crude cell extracts were added
to prewarmed mixtures. For inhibition assays, DCS was added at 10, 50, or 100
mg ml21. Reactions were terminated by boiling for 10 min. Subsequently, 0.25 mg
of D-amino acid oxidase (Boehringer Mannheim), 0.2 mM NADH (Sigma), and
10 U of lactate dehydrogenease (Sigma) were added. The coupled reaction was
measured by the change in absorbance at 340 nm after overnight incubation at
37°C. All controls and samples were measured in triplicate. For the calculation
of specific activities, the background change in absorbance (obtained with boil-
ing-inactivated extracts processed in an identical manner) was subtracted from
the change in absorbance obtained with active extracts. From this net absorbance
change (DA340), the specific activity (in micromoles of L-alanine per minute per
milligram) was calculated by using the following equation: [DA340/t]/[6.2 3 CP],
where t is time (in minutes), 6.2 is the constant used to convert from A340 into
micromoles (in milliliters per micromole, and CP is protein concentration (in
milligrams per milliliter of reaction mixture). No net change in absorbance was
detected with active extracts when L-alanine was omitted from the reaction
mixtures.
The b-galactosidase activity was determined in crude extracts as described
previously (29). Pilot experiments were performed for each cell extract to de-
termine the optimal incubation time and protein concentration resulting in a
linear hydrolysis of b-o-nitrophenylgalactoside. Units of b-galactosidase activity
per milligram were calculated as follows: (DA420 of sample 2 DA420 of control)
3 380/(t 3 AP), where 380 is the constant used to convert from A420 into
b-galactosidase units. t is time (in minutes) at 28°C, and AP is amount of protein
(in milligrams) in the reaction mixture.
Nucleotide sequence accession number. Sequence data corresponding to the
M. smegmatis D-alanine racemase gene cloned in pBUN19 and flanking se-
quences appear in the EMBL/GenBank/DDBJ nucleotide sequence data librar-
ies under accession no. U70872.
RESULTS
Cloning and characterization of M. smegmatis DCS resis-
tance determinants. DCSr mutants of M. smegmatis were iso-
lated, and a genomic library of a mutant strain was constructed
in a multicopy plasmid. By using this type of cloning strategy,
either wild-type genes producing a DCSr phenotype due to a
gene dosage effect or genes with dominant mutations encoding
proteins which are insensitive to drug inhibition can be iso-
lated. However, this strategy does not readily identify muta-
tions involved in DCS transport. In this work, two spontaneous
DCSr mutants, GPM14 and GPM16, were isolated at 500 and
600 mg of DCS ml21, respectively, from the DCS-sensitive
(DCSs) strain mc2155 with a frequency of 1.0 3 1029. These
DCSr strains were identical to the parent strain with respect to
generation time, colony morphology, phage susceptibility, and
susceptibility to antimicrobial agents other than DCS, indicat-
ing that these mutants carry a mutation(s) specific for DCS
resistance. The mutant strain GPM16 was selected for the
construction of a genomic library.
The genomic library was constructed in E. coli-Mycobacte-
rium shuttle plasmid pMV262, which replicates with a copy
number of 5 to 10 in mycobacteria and carries the kanamycin
resistance selection marker (7) (Table 1). The library was
transferred to the DCSs strain mc2155 for the isolation of
transformants resistant to kanamycin and DCS. Plating of a
representative library (approximately 4,000 recombinants) led
to the isolation of a recombinant plasmid (pBUN19) carrying
a 3.1-kb insert. Retransformation of the DCSs strain mc2155
with this plasmid resulted in 100% of the transformants dis-
playing a DCSr phenotype, indicating that a DCS resistance
determinant(s) was present in pBUN19.
The DCSr phenotypes of mutants, recombinants, and con-
trols were characterized by the inhibition of colony formation
at increasing DCS concentrations (Fig. 1). The control group,
strains mc2155 and mc2155(pMV262), had approximately the
same susceptibility to DCS (P 5 0.80). Strains GPM14,
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GPM16, and mc2155(pBUN19) were significantly more resis-
tant than the control group (P , 0.00001).
ORF and subcloning analysis of the DCS resistance deter-
minant. Nucleotide sequence analysis of the 3,059-bp DNA
insert from pBUN19 revealed two open reading frames
(ORFs) (Fig. 2). ORF1 (1,236 nucleotides) has significant ho-
mology with the E. coli glutamate decarboxylase gene, (gadS
[28], or gadA [42]). ORF2 (1, 167 nucleotides) encodes a prod-
uct with significant homology to D-alanine racemases from
several microbial species. The M. smegmatis D-alanine race-
mase gene and its immediate flanking regions were sequenced.
An initiation codon (ATG) at position 51 and a putative ribo-
somal binding site (GAGAT) separated from the initiation
codon by 7 bp were identified. Subcloning experiments were
performed to further localize the DCSr determinant within the
3.1-kb insert of pBUN19. The ScaI/HindIII DNA fragment
subcloned in pBUN82, which contains the complete D-alanine
racemase gene (alrA) but only a truncated glutamate decar-
boxylase gene (gadA), was sufficient for a DCSr phenotype
(Fig. 2). In contrast, subcloning of the 2.0-kb DraI/ClaI frag-
ment in plasmid pBUN83, which contains the gadA gene, gave
a DCSs phenotype. Furthermore, subcloning of DNA frag-
ments into pMV262, which split alrA (plasmids pBUN25 and
pBUN47D), resulted in DCSs transformants (Fig. 2). Hence,
alrA is necessary and sufficient to confer DCSr to mc2155.
The presence of homologous alrA alleles in pathogenic my-
cobacteria was tested by Southern analysis with the D-alanine
racemase gene amplified by PCR as a probe (Fig. 3). This
probe hybridized under stringent conditions with chromosomal
DNA from M. smegmatis, M. intracellulare mc276, Mycobacte-
rium paratuberculosis ATCC 19698, M. bovis BCG, and M.
tuberculosis. Digestion of M. smegmatis mc2155 DNA with
BamHI, EcoRI, and HindIII yielded single bands of 7.3, 10.8,
and 20 kb, respectively. Digestion with PstI, which cuts once
within M. smegmatis alrA, revealed two bands of 6.4 and 1.2 kb
in M. smegmatis, single bands of 7.4 and 5.5 in M. intracellulare
and M. paratuberculosis, and bands of 9.5, 7.1, and 0.9 kb in
strains of the M. tuberculosis complex. The banding pattern of
the M. smegmatis DNA PstI digest differed from the pattern
obtained with the recombinant plasmid pBUN19, which pos-
sesses a noncontiguous Sau3A DNA fragment (ca. 0.5 kb)
upstream from alrA which carries a PstI site.
FIG. 2. Subcloning analysis of pBUN19 and the DCS-resistant phenotype. The position of the Phsp60 promoter in vector pMV262 is indicated. M. smegmatis
sequences (open boxes) and the locations of ORFs are shown. The DCS resistance phenotypes of corresponding subclones are indicated by plus (resistant) and minus
(sensitive) signs.
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Sequence analysis of the M. smegmatis D-alanine racemase
(alrA) gene. The alignment of the inferred amino acid se-
quences of D-alanine racemases from several bacterial species
is displayed in Fig. 4. The predicted 41.0-kDa polypeptide
displayed 66% amino acid identity to the homologous pre-
dicted polypeptides in M. leprae (17) (accession no. U00020)
and M. tuberculosis (35) (accession no. Z77165). The M. smeg-
matis polypeptide has approximately 35% identity to the D-
alanine racemase isozymes from Bacillus stearothermophilus (2,
43), Bacillus subtilis (14), E. coli (5, 27), and Salmonella typhi-
murium (49, 50) and the putative enzyme from Haemophilus
influenzae (15). Multiple amino acid sequence alignments
showed highly conserved domains: the amino acid sequence
A66VVKANAYGHG76 in the consensus, which contributes to
the pyridoxal phosphate binding domain in the active site (18),
and the conserved lysine which covalently binds pyridoxal
phosphate in the catalytic cycle (2, 39). All the mycobacterial
D-alanine racemases display a two-domain structure, as ob-
served in the isozymes from S. typhimurium (19). In this larger
alignment, the consensus at the hinge region that links the two
domains is defined as V302-YG--W308.
Analysis of D-alanine racemase activity and the inhibitory
effect of DCS in M. smegmatis. We determined the D-alanine
racemase specific activity of cell extracts from the parent strain,
i.e., mc2155, mutant GPM16, and recombinant strain mc2155
(pBUN19) (Fig. 5). The D-alanine racemase activity in each
cell extract was inhibited by DCS in a concentration-dependent
manner. Degrees of inhibition by DCS were similar for all
these strains (data not shown). These results confirmed that
D-alanine racemase is one of the drug targets. Surprisingly, the
mutant GPM16 displayed levels of D-alanine racemase and a
pattern of DCS inhibition similar to that of the wild-type strain.
Therefore, its resistance phenotype appears to be due to a
mutation in a separate DCS resistance determinant, distinct
from the D-alanine racemase gene. In contrast, the recombi-
nant strain had a 15-fold-higher specific activity. We hypothe-
sized that the resistance phenotype in the recombinant strain
was the consequence of elevated expression of the wild-type
D-alanine racemase gene harbored in the multicopy vector. To
verify this hypothesis, a cosmid library of the wild-type strain
mc2155 was screened with the objective of identifying and
analyzing the D-alanine racemase gene. The recombinant plas-
mid pBUN66 was isolated by colony hybridization with the
DraI-HindIII fragment from pBUN19 as a probe (see Materi-
als and Methods). The wild-type D-alanine racemase nucle-
otide gene and flanking sequences in pBUN66 were PCR
amplified and sequenced. The D-alanine racemase gene in
pBUN66 was identical to the one cloned in pBUN19, confirm-
ing that the mutant GPM16 had a wild-type D-alanine race-
mase gene. Therefore, this result together with the biochemical
data strongly suggests that the DCS-resistant phenotype of the
recombinant strain mc2155(pBUN19) was due to an overex-
pression of the D-alanine racemase gene and not a mutation in
the structural gene. Furthermore, the recombinant plasmid
pBUN92 (Fig. 2), which does not carry the Phsp60 promoter,
exhibits a DCSr phenotype as well. Hence, multiple copies of
the wild-type D-alanine racemase gene appear to cause the
DCSr phenotype of the recombinant strain. In agreement with
the E. coli (5) (accession no. U00006) and M. leprae (17) (ac-
cession no. U00020) designations, we propose the designation
alrA for the M. smegmatis D-alanine racemase gene, which is
constitutively expressed (6).
Overproduction of D-alanine racemase is also a mechanism
of resistance in spontaneous M. smegmatis DCSr mutants.
Since the observation of the overproduction of D-alanine race-
mase in the recombinant strain mc2155(pBUN19) was the re-
sult of a laboratory manipulation, we analyzed four additional
DCSr independent mutants derived from mc2155. The crude
extract of one of these mutants, GPM14, displayed levels of
D-alanine racemase specific activity similar to those displayed
by the recombinant strain mc2155(pBUN19) (Fig. 5). The
spontaneous DCSr mutant GPM14 exhibited approximately
20-fold-greater D-alanine racemase specific activity than the
DCSs strain mc2155. The D-alanine racemase activity of
GPM14 was inhibited by DCS in a fashion similar to that of the
wild-type enzyme. In agreement with the enzyme activity as-
says, Northern blot analysis demonstrated a 30-fold overex-
pression of D-alanine racemase alrA mRNA in GPM14 com-
pared to that in strain mc2155 (data not shown).
A promoter-up mutation leads to the overexpression of the
D-alanine racemase (alrA) gene in M. smegmatis DCSr mutant
GPM14. The D-alanine racemase allele from GPM14 was PCR
amplified and sequenced. Nucleotide sequence analysis did not
show any mutation within the structural gene but revealed a
single base change, T for G, in the upstream noncoding re-
gions. The identification of the DCSr mutant GPM14, which
possessed an elevated level of D-alanine racemase specific ac-
tivity but an unaltered D-alanine racemase structural gene,
established solid evidence that overproduction of this enzyme
could occur by a natural mechanism.
Mapping of the mRNA start site in mc2155 and GPM14 was
carried out by primer extension analysis (Fig. 6). In each case,
two start sites, one nucleotide apart, were found 13 and 14 bp
upstream from the amino acid start codon, with the product of
the shorter sequence being more abundant. The point muta-
tion in GPM14 was located within the putative 210 promoter
FIG. 3. (A) Southern blot of total DNA from M. smegmatis digested with
BamHI (lane 1), EcoRI (lane 2), HindIII (lane 3), and PstI (lane 4). (B) Southern
blot of total DNA from different mycobacterial species digested with PstI: M.
intracellulare mc276 (lane 1), M. paratuberculosis ATCC 19698 (lane 2), M. bovis
BCG-Pasteur (lane 3), and M. tuberculosis H37Ra (lane 4), H37Rv (lane 5), and
Erdman (lane 6). Blots were hybridized with the radiolabeled 1,092-bp PCR
fragment from pBUN19 under stringent conditions as indicated in Materials and
Methods.
FIG. 4. Multiple sequence alignment of bacterial D-alanine racemases that exhibit similarity to the M. smegmatis ORF2 DCS resistance determinant from pBUN19
(Msmegm). Black boxes indicate complete identity, and shaded boxes indicate conservative amino acid substitutions. Sequences were obtained from GenBank. The
sequences are from various organisms as follows: Bsth-Cat, B. stearothermophilus (catabolic isozyme; accession no. M19142 [43]); Bsubt, B. subtilis (accession no.
M16207 [14]); Mleprae, M. leprae (accession no. U00020 [17]); Mtb, M. tuberculosis (accession no. Z77165 [35]); Ecoli-Cat, E. coli (catabolic isozyme; accession no.
L02948 [27]); Styph-Cat, S. typhimurium (catabolic isozyme; accession no. K02119 [49]); Styph-Bio, S. typhimurium (biosynthetic isozyme; accession no. M12847 [18]);
Ecoli-Bio, E. coli (biosynthetic isozyme; accession no. U00006 [5]); and Hinf-Bio, H. influenzae (biosynthetic isozyme; accession no. L46206 [15]).
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box at position 213 in the short transcript. Quantification of
radioactivity in the primer extension bands demonstrated that
both the shorter and longer transcripts of GPM14 (DCSr) were
overproduced approximately 15-fold with respect to those in
mc2155 (DCSs).
To assess whether the point mutation in the promoter region
of the D-alanine racemase gene of mutant strain GPM14 was
responsible for changes in the promoter strength, transcrip-
tional fusions to a reporter gene were performed. The ScaI-
ClaI fragments (Fig. 2), which included approximately 500 bp
of the noncoding region of the D-alanine racemase gene from
wild-type (mc2155) and mutant (GPM14) strains, were sub-
cloned into the promoter-probe vector pCV77 (Table 1) up-
stream from the promoterless lacZ gene. These promoter con-
structs were transformed into wild-type M. smegmatis mc2155,
and b-galactosidase activities were measured. The expression
from the construct containing the GPM14 alrA promoter was
approximately 50-fold higher than the expression from the
respective mc2155 promoter. These results (Table 2) con-
firmed that a point mutation, which increases the %AT of the
putative 210 box of the alrA gene, led to a significant increase
in the level of gene expression.
Overexpression of the M. smegmatis D-alanine racemase
(alrA) gene from a multicopy plasmid in M. intracellulare and
M. bovis BCG leads to a DCS-resistant phenotype. To deter-
mine if the overproduction of D-alanine racemase could also
confer a DCSr phenotype in pathogenic mycobacteria, recom-
binant plasmid pBUN19 was electrotransformed into M. intra-
cellulare mc276 and M. bovis BCG. The susceptibilities of the
wild-type and transformant strains to DCS are depicted in Fig.
7. These mycobacterial species are inherently more susceptible
to DCS than M. smegmatis. As illustrated, the M. intracellulare
strain mc276(pBUN19) is more resistant to DCS than the par-
ent strain transformed with plasmid vector pMV262 (P ,
0.01). Colony morphology changes were noticed at DCS con-
centrations higher than 40 mg ml21 in M. intracellulare. A
similar profile was obtained with M. bovis BCG, where the
transformant with plasmid pBUN19 was more resistant than
the control strain carrying cloning vector pMV262 (P , 0.05).
Taken together, these data indicate that multiple copies of a
wild-type D-alanine racemase gene can confer a DCS-resistant
phenotype in M. intracellulare and M. bovis BCG.
DISCUSSION
In this study, we identified a gene from M. smegmatis that
confers a DCS-resistant phenotype to a wild-type DCS-sensi-
tive host when cloned into a multicopy vector. This represents
the first molecular genetic analysis of DCS targets in mycobac-
teria. The mechanisms of DCS resistance in mycobacteria have
not been thoroughly investigated. Since DCS can inhibit sev-
eral pyridoxal phosphate enzymes (31), the existence of more
than one mechanism leading to DCS resistance is likely. In
addition, multiple-step DCSr mutants of mycobacteria were
isolated in previous studies (46) as well as in our laboratory.
The mechanisms relevant to DCS resistance in mycobacteria
are presented in the model depicted in Fig. 8. DCS may enter
the mycobacterial cell by either diffusion or uptake via a spe-
cific transporter (48). Mutations in the transporter gene reduc-
ing DCS binding or eliminating the transporter from the cell
surface may lead to reduced DCS uptake and increased DCS
resistance. Similarly, a mutation in a gene coding for an efflux
pump may lead to higher affinity for DCS, with the concomi-
tant expulsion of the drug. Alternatively, it is possible that a
mutational change could increase the affinity or the levels of a
drug-detoxifying enzyme which would derivatize or hydrolyze
DCS. The overproduction of a protein target(s) could lead to
increased resistance due to the sequestration or removal of the
FIG. 5. Analysis of M. smegmatis D-alanine racemase activities. Enzyme ac-
tivity was determined in cell extracts from cells grown in minimal medium (55)
without DCS. Specific activities are expressed as micromoles of L-alanine per
minute per milligram (means 6 standard deviations of triplicate measurements).
FIG. 6. Primer extension analysis of the alrA transcript. Total RNA (50 mg)
from mc2155 or GPM14 cells was annealed to an oligonucleotide of the alrA gene
and extended as described in Materials and Methods. Lanes A, C, G, and T
display a dideoxy sequencing ladder of the wild-type alrA gene generated with
the same oligonucleotide primer. Nucleotides at the two start sites are indicated
by asterisks. The target site for the mutation in the promoter region is boxed.
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drug by the excess target protein. The latter mechanism would
effectively reduce the free intracellular DCS concentration,
which would also protect other potential protein targets from
drug inhibition. If DCS interacts with more than one target
protein (such as D-alanine racemase and D-alanine ligase), it is
unlikely that mutations in one of the structural genes alone
would lead to primary DCS resistance. In this study, we pre-
sented evidence that one of the mechanisms of DCS resistance
in M. smegmatis involves the overexpression of the alrA gene
due to a promoter-up mutation. In agreement with our find-
ings, a similar mechanism of DCSr involving the overproduc-
tion of either D-alanine racemase or D-alanine ligase enzyme
activities, possibly mediated by wild-type products, was de-
scribed for streptococci (38).
We have shown that D-alanine racemase is a target of DCS
and that a natural mechanism of resistance is the overproduc-
tion of the enzyme due to a promoter-up mutation. An inter-
esting finding was that the original DCSr mutant, GPM16, used
as a source of DNA for the cloning experiments did not possess
elevated levels of D-alanine racemase. Hence, the resistance
mechanism in GPM16 and three other mutants is not related
to the D-alanine racemase determinant. We are currently in-
vestigating another DCSr clone carrying a different DCS resis-
tance determinant (6).
Soon after the introduction of DCS as an antituberculosis
drug about 40 years ago, DCSr clinical isolates of M. tubercu-
losis were readily isolated (8). Since those first trials, DCS has
not been administered frequently or alone due to its toxicity in
patients. As a consequence, the current panel of DCSr clinical
isolates of pathogenic mycobacteria is limited and may not be
representative of the situation that would arise in therapy with
DCS. Once we identified a DCSr determinant in M. smegmatis
and showed its conservation within the genus, we tested
whether a similar mechanism of DCS resistance could occur in
members of the pathogenic mycobacterial groups by trans-
forming M. intracellulare and M. bovis BCG with a multicopy
plasmid carrying the M. smegmatis alrA gene. DCSr transfor-
mants were obtained, suggesting that AlrA overproduction is a
potential mechanism of DCS resistance in clinical isolates of
M. tuberculosis and other pathogenic mycobacteria. Further-
more, the homology between M. smegmatis AlrA and the M.
leprae and M. tuberculosis counterparts suggests a potential
utility of M. smegmatis as a surrogate host for the study of the
AlrA enzymes from pathogenic species.
Since racemases are absent from mammalian cells, these
bacterial enzymes are excellent targets for antibiotic develop-
ment (47). Several compounds were developed but were never
advanced into clinical use due to their toxicity in humans (32).
FIG. 7. Inhibition of CFU at increasing DCS concentrations. (Left) Comparison of M. intracellulare strains mc276(pMV262) (open triangles) and mc276(pBUN19)
(closed triangles). (Right) Comparison of M. bovis BCG(pMV262) (open circles) and BCG(pBUN19) (closed circles). The asterisks indicate the concentrations at which
changes in colony morphology (from opaque white domed to transparent flat colonies) were observed. For analysis of statistical significance, see the text.
TABLE 2. Expression of b-galactosidase activity in recombinant M. smegmatis carrying transcriptional fusions to alrA upstream sequences
Source of alrA
upstream sequence Plasmid Relevant alrA upstream sequence
a Sp act of
b-galactosidaseb
None pCV77 None 0.42 6 0.01
mc2155 pBUN101 GGGACAATGGGCGCCGGAGATTATGACGATG 7.92 6 0.01
GPM14 pBUN102B GGTACAATGGGCGCCGGAGATTATGACGATG (3.6 6 0.2) 3 102
a The putative 210 box, Shine-Dalgarno sequence, and ATG start codon for the alrA gene are underlined; the T-for-G transversion in the upstream noncoding
sequences and the transcriptional start site are shown in boldface type. The transversion increases the similarity of the putative 210 box with the consensus E. coli Es70
promoter (37) and the general consensus established for M. smegmatis and M. tuberculosis promoters (4).
b The specific activities of b-galactosidase from M. smegmatis mc2155 transformants carrying promoter constructs are expressed in units/milligram of protein
(means 6 standard deviations of triplicate measurements).
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The D-alanine racemase gene of mycobacteria may be a pow-
erful tool for the rational design of effective and less toxic DCS
derivatives and D-alanine analogs against M. tuberculosis and
other pathogenic mycobacteria. A structure-based layout in
which computational and crystallography methods are com-
bined would advance the rational design of a new generation of
drugs. A key ingredient to the success of this strategy is the
identification of the DCS lethal target(s) in pathogenic myco-
bacteria whose inhibition leads to cell death.
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